Stiris Research Inc. Awarded Global Hereditary Angioedema Trial

London, ON — February 15, 2024 —

Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announces the award of a Hereditary Angioedema (HAE) study.

“All of us at Stiris are excited to embark on this rare disease trial. Our highly experienced team is looking forward to working with the global trial and getting novel therapy into patients suffering from this rare disease.  Stiris’ “why” is to improve the lives of others, and this is exactly the type of work we are passionate about, and it allows us to continue to achieve our why” said Shantal Feltham, President & CEO.

Hereditary angioedema is a rare inherited disorder characterized by recurrent episodes of the accumulation of fluids outside of the blood vessels, blocking the normal flow of blood or lymphatic fluid and causing rapid swelling of tissues in the hands, feet, limbs, face, intestinal tract, or airway. These symptoms develop as the result of deficiency or improper functioning of certain proteins that help to maintain the normal flow of fluids through very small blood vessels. (

About Stiris Research

Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.

For more information, please contact:

Marketing – Stiris Research Inc.